Journal of Neural Transmission

, 118:1255

Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study

  • Michael Rainer
  • A. Wuschitz
  • C. Jagsch
  • C. Erb
  • J.-J. Chirikdjian
  • H. A. M. Mucke
Dementias - Short Communication

DOI: 10.1007/s00702-011-0623-8

Cite this article as:
Rainer, M., Wuschitz, A., Jagsch, C. et al. J Neural Transm (2011) 118: 1255. doi:10.1007/s00702-011-0623-8

Abstract

Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer’s disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this ‘real-life’ setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.

Keywords

Alzheimer’s diseaseDementiaMemantineActivities of daily livingPost-marketing‘Real-life’ setting

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Michael Rainer
    • 1
  • A. Wuschitz
    • 2
  • C. Jagsch
    • 3
  • C. Erb
    • 4
  • J.-J. Chirikdjian
    • 5
  • H. A. M. Mucke
    • 6
  1. 1.Memory Clinic and Psychiatric DepartmentDonauspital Sozialmedizinisches Zentrum OstWienAustria
  2. 2.Practice for Psychiatry and NeurologyWienAustria
  3. 3.Psychiatric Hospital WelsWelsAustria
  4. 4.Merz PharmaceuticalsFrankfurt/MainGermany
  5. 5.Zak Pharma GmbHWienAustria
  6. 6.H. M. Pharma ConsultancyWienAustria